allergan

Allergan snaps up Vitae Pharma for $639 million

pharmafile | September 15, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Vitae, acquisition 

Allergan has agreed to buy clinical-stage biotech Vitae Pharmaceuticals for $639 million, or $21 a share – more than double its market value.

The company hopes to bolster its skin-care pipeline with the acquisition, as it takes control of a range of products to treat atopic dermatitis, eczema, and most critically psoriasis, a $49 billion market.

“The acquisition of Vitae is a strategic investment for Allergan that adds strength and depth to our innovative medical dermatology franchise,” commented Allergan chief executive Brent Saunders.

Advertisement

David Nicholson, Allergan’s chief research and development officer, added: “Vitae’s novel Contour drug discovery platform and its team, which have been instrumental in the discovery of novel ‘difficult to drug’ compounds, will be highly complementary to Allergan’s existing R&D discovery efforts in key therapeutic areas.”

Matt Fellows

Related Content

Brenntag acquires mcePharma to expand GMP capabilities in biopharma services

Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries …

handshake_2

Curium Pharma announces acquisition of Monrol

Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine …

Enosium Life Science acquires RWEality

Enosium Life Science, which specialises in life sciences, has acquired RWEality, a consultancy focused on …

The Gateway to Local Adoption Series

Latest content